Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers

BACKGROUND: Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease-modifying therapies for relapsing multiple sclerosis (MS). Observational studies are valuable when randomized clinical trials cannot be done due to ethical or practical reasons. Two-site studies allow investigators to...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurol Clin Pract
Egile Nagusiak: Vollmer, Brandi, Ontaneda, Daniel, Bandyopadhyay, Anasua, Cohn, Sam, Nair, Kavita, Sillau, Stefan, Bermel, Robert A., Corboy, John R., Fox, Robert J., Vollmer, Timothy, Cohen, Jeffrey A., Alvarez, Enrique, Hersh, Carrie M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2018
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105060/
https://ncbi.nlm.nih.gov/pubmed/30140580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000487
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak